Hims & Hers ceases sale of Wegovy knockoff

Health company Him & Hers says it will stop sales of drugs using compounded GLP-1s following backlash from the Food & Drug Administration as well as a lawsuit by Novo Nordisk, the maker of popular drugs Wegovy and Ozempic. In a post on X that generated more than 1 million views, San Francisco-based Hims & Hers says it has had “constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment.” Company stock plummeted 20% on the news Monday and is down 50% on the year.